Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]
Business Overview:[1][2]a)JPL provides essential medicines for women-specific healthcare needs, throughGynaecology and Orthopaedicsas its focus segments.b)It is also present in major therapeutic sub-segments viz. antibiotics, allergy management, immunity and cell protection, OTC products, dermatology and pediatrics segmentc)JPL has17brands amongst Top 5 brands in the molecule category. It has a pan-India presence through its strong sales team of900+individuals. In FY24, company generated ~47%of its revenues from its top 5 brands and ~67%from its top 7 brands
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Sun Pharma.Inds. | 1669.20 | 34.70 | 400532.32 | 0.96 | 3124.95 | 2.56 | 14478.31 | 8.93 | 20.21 | 54964.01 | 30.12 | 11543.96 | 3117.95 | 5.15 | 12.97 | 0.07 |
| 2. | Divi's Lab. | 6233.95 | 66.59 | 165459.25 | 0.48 | 689.00 | 35.10 | 2715.00 | 16.12 | 20.44 | 10029.00 | 32.37 | 2485.00 | 689.00 | 10.74 | 13.53 | 0.01 |
| 3. | Torrent Pharma. | 4018.75 | 62.76 | 135973.70 | 0.80 | 591.00 | 32.49 | 3302.00 | 14.30 | 27.05 | 12248.00 | 32.60 | 2166.53 | 600.17 | 16.10 | 13.26 | 0.33 |
| 4. | Cipla | 1397.95 | 20.76 | 112914.51 | 0.93 | 1353.37 | 3.73 | 7589.44 | 7.64 | 22.72 | 28349.57 | 25.40 | 5441.14 | 1351.17 | 3.43 | 14.72 | 0.01 |
| 5. | Lupin | 2174.20 | 22.97 | 99357.92 | 0.55 | 1484.83 | 73.34 | 7047.51 | 24.23 | 21.30 | 24750.69 | 27.25 | 4324.63 | 1477.92 | 5.06 | 12.41 | 0.32 |
| 6. | Dr Reddy's Labs | 1179.30 | 17.05 | 98432.10 | 0.68 | 1336.80 | 7.28 | 8828.30 | 9.83 | 22.69 | 34310.00 | 24.64 | 5772.20 | 1347.10 | 2.73 | 12.95 | 0.16 |
| 7. | Mankind Pharma | 2173.55 | 51.33 | 89745.24 | 0.05 | 520.18 | -22.00 | 3697.16 | 20.77 | 15.98 | 13545.67 | 24.12 | 1748.55 | 511.51 | 5.87 | 8.89 | 0.55 |
| 8. | Jagsonpal Pharma | 176.30 | 26.84 | 1174.01 | 1.42 | 12.57 | 9.69 | 74.47 | -0.29 | 22.95 | 282.67 | 19.52 | 43.75 | 12.57 | 4.65 | 16.03 | 0.03 |
| – | Median: 149 Co. | 390.6 | 30.03 | 1766.0 | 0.11 | 13.49 | 11.71 | 161.76 | 10.58 | 14.89 | 591.73 | 15.93 | 45.26 | 13.96 | 3.13 | 8.56 | 0.22 |
Standalone figures in ₹ crores
| Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 61 | 60 | 55 | 60 | 58 | 47 | 43 | 61 | 75 | 74 | 59 | 76 | 74 |
Expenses | 48 | 52 | 50 | 52 | 49 | 44 | 41 | 51 | 58 | 58 | 50 | 61 | 58 |
Operating Profit | 13 | 9 | 5 | 9 | 8 | 3 | 3 | 10 | 16 | 16 | 9 | 14 | 16 |
Other Income | 1 | 2 | 3 | 2 | 2 | 3 | 2 | -2 | 2 | 26 | 3 | 3 | 3 |
Profit before tax | 14 | 10 | 7 | 10 | 10 | 5 | 5 | 7 | 15 | 39 | 9 | 14 | 17 |
Tax % | 24% | 21% | 24% | 26% | 25% | 25% | 22% | 25% | 25% | 17% | 24% | 25% | 25% |
Net Profit | 10 | 8 | 6 | 7 | 7 | 4 | 4 | 5 | 11 | 32 | 7 | 11 | 13 |
EPS in Rs | 1.59 | 1.19 | 0.85 | 1.14 | 1.14 | 0.60 | 0.54 | 0.81 | 1.73 | 4.82 | 0.99 | 1.62 | 1.89 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 144 | 138 | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 283 |
Expenses | 133 | 129 | 132 | 138 | 138 | 157 | 150 | 169 | 192 | 203 | 186 | 218 | 227 |
Operating Profit | 11 | 9 | 12 | 6 | -11 | 9 | 9 | 19 | 26 | 34 | 23 | 51 | 55 |
Other Income | 0 | 0 | 1 | 13 | 0 | 1 | 3 | 4 | 3 | 2 | 9 | 28 | 34 |
Interest | 5 | 4 | 5 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
Depreciation | 3 | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 8 | 9 |
Profit before tax | 3 | 2 | 4 | 14 | -12 | 9 | 9 | 22 | 27 | 35 | 30 | 70 | 79 |
Net Profit | 2 | 1 | 3 | 12 | -12 | 7 | 8 | 17 | 19 | 27 | 22 | 55 | 62 |
EPS in Rs | 0.32 | 0.18 | 0.50 | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.40 | 8.34 | 9.32 |
Dividend Payout % | 62% | 22% | 8% | 2% | -2% | 9% | 17% | 15% | 56% | 49% | 59% | 30% | – |
Standalone figures in ₹ crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
Reserves | 85 | 82 | 85 | 97 | 85 | 91 | 98 | 109 | 120 | 146 | 174 | 227 | 240 |
Borrowings | 36 | 39 | 38 | 8 | 8 | 4 | 5 | 7 | 0 | 6 | 9 | 9 | 9 |
Other Liabilities | 22 | 19 | 22 | 25 | 23 | 28 | 31 | 35 | 31 | 30 | 21 | 29 | 37 |
Total Liabilities | 156 | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 299 |
Fixed Assets | 56 | 52 | 52 | 22 | 21 | 22 | 22 | 26 | 23 | 24 | 9 | 94 | 90 |
Gross Block | 87 | 88 | 90 | 53 | 54 | 55 | 56 | 60 | 58 | 33 | 12 | 103 | – |
Accumulated Depreciation | 31 | 36 | 39 | 31 | 32 | 33 | 34 | 34 | 36 | 9 | 2 | 9 | – |
CWIP | 2 | 0 | 0 | 0 | 3 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 15 | 51 | 1 | 0 | 0 | 0 |
Other Assets | 98 | 102 | 108 | 121 | 105 | 110 | 109 | 123 | 91 | 170 | 208 | 184 | 209 |
Total Assets | 156 | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 299 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | 8 | 4 | 9 | -3 | -2 | 31 | 11 | 28 | 7 | 47 | 35 | 55 |
Cash from Investing Activity | -1 | -0 | -2 | 41 | -3 | -1 | -11 | -2 | -26 | -58 | -25 | -45 |
Cash from Financing Activity | -4 | -1 | -6 | -34 | -1 | -6 | -1 | -7 | -18 | -0 | -9 | -12 |
Net Cash Flow | 2 | 2 | 1 | 5 | -6 | 24 | -0 | 19 | -36 | -11 | 2 | -2 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 115 | 119 | 106 | 100 | 73 | 45 | 49 | 25 | 26 | 32 | 19 | 18 |
Inventory Days | 173 | 176 | 246 | 295 | 307 | 164 | 191 | 134 | 122 | 82 | 68 | 58 |
Days Payable | 29 | 42 | 60 | 56 | 54 | 59 | 76 | 82 | 76 | 66 | 35 | 37 |
Cash Conversion Cycle | 259 | 252 | 292 | 339 | 325 | 150 | 164 | 77 | 72 | 48 | 53 | 39 |
Working Capital Days | 64 | 68 | 72 | 154 | 149 | 67 | 55 | 32 | 59 | 34 | 52 | 9 |
ROCE % | 6% | 5% | 7% | 3% | -10% | 9% | 9% | 18% | 20% | 25% | 17% | 23% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Stock Analysis
Jagsonpal Pharmaceuticals Ltd. is a pharmaceutical company incorporated in 1978, focusing on the manufacturing and trading of pharmaceutical products. Its key therapeutic areas include Gynaecology and Orthopaedics.
The company's growth is supported by a strong portfolio of leading brands, which contribute significantly to its revenue. It possesses a pan-India presence and a dedicated sales team of over 900 individuals, ensuring wide market reach.
Currently no data available for Order Book.
Historically, the company has reported subdued sales growth over a five-year period. Additionally, it is contesting a tax demand order of approximately ₹1.52 crore related to FY22, with an appeal filed, indicating potential regulatory overhang.
Corporate Announcements
